Cullinan Therapeutics, Inc. Share Price

Cullinan Therapeutics, Inc. Share Price

NASDAQ: CGEM | Small Cap
$15.45
-$0.13 (-0.83%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Cullinan Therapeutics, Inc. Stock Performance

Open
$15.84
Prev. Close
$15.58
Circuit Range
N/A
Day Range
$15.37 - $16.08
Year Range
$6.75 - $23.16
Volume
30,819
Average Traded
$15.63

Cullinan Therapeutics, Inc. Share Price Today

As of 30 October 2026, Cullinan Therapeutics, Inc.'s share price is $15.45. The stock opened at $15.84, compared to its previous close of $15.58. During today's trading session, Cullinan Therapeutics, Inc.'s share price traded between $15.37 and $16.08, with an average price of $15.72. Over the past 52 weeks, the stock has recorded a high of $23.16 and a low of $6.75. In terms of performance, Cullinan Therapeutics, Inc.'s share price has risen by 18.48% over the last six months and is up 78.20% on a year-on-year basis.

Cullinan Therapeutics, Inc. Share Price Chart

Line chart of the Cullinan Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 15.37 to 16.14, ending at 15.45.
$15.37$16.08
L
Show Current Price
H

Cullinan Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$912.32M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.78
Revenue (TTM)
$0.00
Return On Equity (TTM)
-55.58%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-6.11%

Cullinan Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$50.61-$29.05-$45.49-$53.70
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A42.60%-56.59%-18.05%

Cullinan Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit$111.21-$133.45-$149.39-$198.21
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-220.00%-11.94%-32.68%

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Cullinan Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$15.21
$15.47
+0.72%
Sep 2026
$21.73
$15.36
-31.85%
Aug 2026
$16.50
$22.54
+36.61%
Jul 2026
$18.05
$16.50
-9.39%
Jun 2026
$15.96
$18.21
+10.80%
May 2026
$13.10
$16.43
+26.04%
Apr 2026
$14.43
$13.04
-8.23%
Mar 2026
$15.25
$14.21
-8.32%
Feb 2026
$12.40
$15.50
+29.60%
Jan 2026
$10.49
$11.96
+15.78%
Dec 2025
$11.33
$10.33
-8.95%
Nov 2025
$8.61
$11.35
+30.85%

CGEM Share Price FAQs